Calidi Biotherapeutics (CLDI) Competitors $0.83 -0.06 (-6.63%) Closing price 04:00 PM EasternExtended Trading$0.86 +0.02 (+2.92%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends CLDI vs. XLO, VYNE, KZR, CELU, ALRN, NBRV, VIRI, ITRM, DTIL, and SCYXShould you be buying Calidi Biotherapeutics stock or one of its competitors? The main competitors of Calidi Biotherapeutics include Xilio Therapeutics (XLO), VYNE Therapeutics (VYNE), Kezar Life Sciences (KZR), Celularity (CELU), Aileron Therapeutics (ALRN), Nabriva Therapeutics (NBRV), Virios Therapeutics (VIRI), Iterum Therapeutics (ITRM), Precision BioSciences (DTIL), and SCYNEXIS (SCYX). These companies are all part of the "pharmaceutical products" industry. Calidi Biotherapeutics vs. Xilio Therapeutics VYNE Therapeutics Kezar Life Sciences Celularity Aileron Therapeutics Nabriva Therapeutics Virios Therapeutics Iterum Therapeutics Precision BioSciences SCYNEXIS Xilio Therapeutics (NASDAQ:XLO) and Calidi Biotherapeutics (NYSE:CLDI) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, valuation, community ranking, earnings, institutional ownership, analyst recommendations, risk and profitability. Is XLO or CLDI more profitable? Calidi Biotherapeutics' return on equity of 0.00% beat Xilio Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Xilio TherapeuticsN/A -211.50% -80.31% Calidi Biotherapeutics N/A N/A -344.45% Which has more volatility & risk, XLO or CLDI? Xilio Therapeutics has a beta of -0.25, indicating that its share price is 125% less volatile than the S&P 500. Comparatively, Calidi Biotherapeutics has a beta of 1.18, indicating that its share price is 18% more volatile than the S&P 500. Does the media favor XLO or CLDI? In the previous week, Xilio Therapeutics had 1 more articles in the media than Calidi Biotherapeutics. MarketBeat recorded 1 mentions for Xilio Therapeutics and 0 mentions for Calidi Biotherapeutics. Xilio Therapeutics' average media sentiment score of 0.49 beat Calidi Biotherapeutics' score of 0.16 indicating that Xilio Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Xilio Therapeutics Neutral Calidi Biotherapeutics Neutral Which has stronger earnings and valuation, XLO or CLDI? Calidi Biotherapeutics has higher revenue and earnings than Xilio Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioXilio TherapeuticsN/AN/A-$76.40M-$1.72-0.72Calidi Biotherapeutics$50K439.24-$29.22MN/AN/A Does the MarketBeat Community believe in XLO or CLDI? Xilio Therapeutics received 12 more outperform votes than Calidi Biotherapeutics when rated by MarketBeat users. CompanyUnderperformOutperformXilio TherapeuticsOutperform Votes1275.00% Underperform Votes425.00% Calidi BiotherapeuticsN/AN/A Do institutionals and insiders believe in XLO or CLDI? 54.3% of Xilio Therapeutics shares are owned by institutional investors. Comparatively, 12.5% of Calidi Biotherapeutics shares are owned by institutional investors. 5.2% of Xilio Therapeutics shares are owned by company insiders. Comparatively, 24.3% of Calidi Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Do analysts recommend XLO or CLDI? Xilio Therapeutics currently has a consensus price target of $4.00, suggesting a potential upside of 223.89%. Calidi Biotherapeutics has a consensus price target of $16.67, suggesting a potential upside of 1,908.03%. Given Calidi Biotherapeutics' higher possible upside, analysts clearly believe Calidi Biotherapeutics is more favorable than Xilio Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Xilio Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Calidi Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryCalidi Biotherapeutics beats Xilio Therapeutics on 7 of the 12 factors compared between the two stocks. Get Calidi Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CLDI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CLDI vs. The Competition Export to ExcelMetricCalidi BiotherapeuticsBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$21.99M$3.00B$5.39B$20.05BDividend YieldN/A1.89%5.37%3.61%P/E RatioN/A45.2288.1041.74Price / Sales439.24293.761,285.4017.65Price / CashN/A189.5236.6017.54Price / Book-0.363.994.955.85Net Income-$29.22M-$40.99M$117.96M$1.01B7 Day Performance-6.30%2.89%2.49%3.52%1 Month Performance-38.97%0.03%3.44%6.02%1 Year PerformanceN/A-0.42%27.06%20.34% Calidi Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CLDICalidi Biotherapeutics3.0694 of 5 stars$0.83-6.6%$16.67+1,897.0%N/A$22.08M$50,000.000.0038XLOXilio Therapeutics3.2382 of 5 stars$1.07-2.7%$4.00+273.8%+67.9%$47.04M$4.62M-0.6270News CoveragePositive NewsVYNEVYNE Therapeutics3.8391 of 5 stars$3.16-7.9%$6.88+117.6%+51.7%$46.61M$493,000.00-3.6730KZRKezar Life Sciences3.9267 of 5 stars$6.32-2.9%$39.50+525.0%-25.4%$46.11M$7M-0.4860CELUCelularity0.3696 of 5 stars$2.08-3.7%N/A-21.8%$45.73M$48.20M0.00220Short Interest ↑Gap UpALRNAileron Therapeutics2.8718 of 5 stars$2.11+9.3%$19.00+800.5%N/A$45.72MN/A-0.689NBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M-0.0770VIRIVirios TherapeuticsN/A$2.36-0.8%$3.00+27.1%+130.6%$45.45MN/A-8.745Gap UpITRMIterum Therapeutics1.8957 of 5 stars$1.65-0.3%$5.00+204.0%-18.9%$45.26MN/A-0.8210Positive NewsDTILPrecision BioSciences4.4668 of 5 stars$5.75+0.9%$37.67+555.1%-56.6%$44.11M$75.10M95.85200Short Interest ↑SCYXSCYNEXIS0.3456 of 5 stars$1.16-5.7%N/A-38.8%$44.02M$8.57M-1.5760Positive News Related Companies and Tools Related Companies Xilio Therapeutics Competitors VYNE Therapeutics Competitors Kezar Life Sciences Competitors Celularity Competitors Aileron Therapeutics Competitors Nabriva Therapeutics Competitors Virios Therapeutics Competitors Iterum Therapeutics Competitors Precision BioSciences Competitors SCYNEXIS Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:CLDI) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredThis coin could surge during Trump’s first week in office.Juan has never had a losing trade on Bitcoin. And he booked gains of 312% on Chainlink … Now, he says one v...Weiss Ratings | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Calidi Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Calidi Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
